Metsera (MTSR) Hits New High on Billion-Dollar Bidding War

Core Insights - Metsera, Inc. (NASDAQ:MTSR) is experiencing significant stock performance due to a billion-dollar bidding war between Pfizer Inc. and Novo Nordisk for its acquisition [1][2] - Pfizer has upgraded its offer to $10 billion to acquire Metsera, matching Novo Nordisk's bid, which is reportedly higher [2][3] - The bidding war began in January, with both companies aiming to expand their presence in the growing weight-loss market [2] Company Developments - Earlier in the year, Pfizer halted a clinical trial for its weight-loss drug due to safety concerns and shifted focus to acquiring Metsera to re-enter the market [3] - Metsera had previously signed a definitive agreement with Pfizer for acquisition but later retracted after Novo Nordisk made a higher offer [3] - Pfizer has initiated legal action against Metsera and Novo Nordisk, claiming breach of the definitive agreement and alleging anticompetitive behavior by Novo Nordisk [4]